| Date | Title | Description |
| 31.03.2026 | Co-PSMA data published in the European Urology journal | SYDNEY, March 31, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment o... |
| 25.03.2026 | Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics | SYDNEY, March 25, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment o... |
| 17.03.2026 | Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal | HIGHLIGHTS
Oral presentation on key results from the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT) was delivered by Prof Louise Emmett (St Vincent's Hospital Sydney) at the European Association of Urology (EAU) Congress 2026 o... |
| 10.03.2026 | Registrational Phase III AMPLIFY trial: Target number of participants achieved | SYDNEY, March 10, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment o... |
| 16.02.2026 | Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial | HIGHLIGHTS
Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released.
The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was accepted for oral presentation a... |
| 15.01.2026 | SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting | HIGHLIGHTS
Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol.
Patient population
With the ... |
| 24.12.2025 | Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026 | SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment ou... |
| 16.10.2025 | Clarity signs copper-67 Supply Agreement with Nusano | SYDNEY, Oct. 16, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment ou... |
| 14.10.2025 | Co-PSMA trial achieves primary endpoint | SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment ou... |
| 17.07.2025 | Co-PSMA trial: Recruitment successfully completed | SYDNEY, July 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment ou... |
| 17.06.2025 | Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx | Highlights
Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for 64Cu-SAR-bisPSMA.
SpectronRx's facility in Indiana will provide on-demand commercial-scale manufacturing of both copper-64 and 64Cu-SAR-bisPSMA und... |
| 13.06.2025 | SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging | Highlights
Topline data from Clarity's diagnostic Phase II trial, SABRE, showed that 64Cu-SAR-Bombesin was safe, well tolerated and effective at detecting prostate cancer in patients with biochemical recurrence (BCR) who are negative or equ... |
| 05.06.2025 | DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway. | HIGHLIGHTS
Topline data from Clarity's diagnostic Phase II trial, DISCO, confirms that 64Cu-SARTATE is safe and highly effective compared to standard-of-care (SOC) imaging at detecting lesions in patients with neuroendocrine tumours (NETs).... |
| 29.05.2025 | First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT | SYDNEY, May 29, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment out... |
| 20.05.2025 | Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences | SYDNEY, May 20, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment out... |
| 17.04.2025 | Advancements in Cancer Treatment: A New Dawn for Prostate and Brain Cancer Therapies | In the ever-evolving landscape of cancer treatment, two recent studies shine a light on innovative therapies that could reshape patient outcomes. The SECuRE trial, focusing on prostate cancer, and the IPAX-Linz study, targeting gliomas, are... |
| 17.04.2025 | Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano | Highlights
Clarity has signed a commercial-scale agreement with Nusano, Inc. ("Nusano") for supply of copper-64 (Cu-64 or 64Cu) isotope.
The 190,000 square foot Nusano facility in West Valley City, Utah is capable of producing mor... |
| 15.04.2025 | SECuRE trial update: First patient treated in the Phase II Cohort Expansion | HIGHLIGHTS
The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of 67Cu-SAR-bisPSMA.This follows the recent recommendation by the Safety Review... |
| 10.03.2025 | Promising Advances in Cancer Treatment: A Look at Recent Developments in Glioblastoma and Prostate Cancer Therapies | In the ever-evolving landscape of cancer treatment, two recent developments stand out: the collaboration between DBP International AB and Vivo Biopharma LLC on SI-053, and the SECuRE trial's promising results for 67Cu-SAR-bisPSMA. Both init... |
| 05.03.2025 | SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences. | HIGHLIGHTS
Safety Review Committee (SRC) meeting confirms end of the Dose Escalation Phase and commencement of the Cohort Expansion Phase (Phase II stage) of the SECuRE study.
Based on the efficacy and safety assessment of all cohorts and t... |
| 19.02.2025 | Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA | SYDNEY, Feb. 19, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment ou... |
| 24.01.2025 | Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer | SYDNEY, Jan. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment ou... |
| 18.12.2024 | Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical | Highlights
Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of copper isotopes for the diagnosis and treatment of cancer.
The product, ter... |
| 16.10.2024 | Clarity Pharmaceuticals' AMPLIFY Trial: A New Dawn for Prostate Cancer Diagnostics | In the world of prostate cancer diagnostics, hope often flickers like a candle in the dark. Clarity Pharmaceuticals is about to turn that flicker into a beacon. The company recently received a green light from the U.S. Food and Drug Adminis... |
| 16.10.2024 | Copper-67 SAR-bisPSMA updates | SYDNEY, Oct. 16, 2024 /PRNewswire/ --
HIGHLIGHTS
Cohort 4 - SECuRE Trial
The third participant of cohort 4 (multi-dose) of the SECuRE trial1 has now completed the Dose Limiting Toxicity (DLT) period after a second dose of 12GBq of 67Cu-SAR-... |
| 14.10.2024 | Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer | Highlights
United States Food and Drug Administration (U.S. FDA) provided positive feedback on a pivotal Phase III trial for 64Cu-SAR-bisPSMA diagnostic in prostate cancer patients with biochemical recurrence (BCR), AMPLIFY.
The positive re... |
| 13.09.2024 | New Frontiers in Cancer Imaging and Treatment: A Look at SECuRE and ZIRCON Trials | In the ever-evolving landscape of cancer treatment, two recent trials have emerged as beacons of hope. The SECuRE trial and the ZIRCON trial are paving the way for innovative therapies and diagnostic tools that could redefine patient care. ... |
| 12.09.2024 | SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort | Highlights
Cohort 4 of the SECuRE trial is the first to assess multiple cycles of 67Cu-SAR-bisPSMA at the highest dose of 12GBq.
The Safety Review Committee (SRC) assessed early data from the first 3 participants in cohort 4 who received 2 ... |
| 22.08.2024 | Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA | SYDNEY, Aug. 22, 2024 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and... |
| 08.03.2024 | Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range | Highlights
Clarity recently reported that in its diagnostic Phase 1/2 trial, COBRA, 64Cu-SAR-bisPSMA was found to be safe and highly effective in detecting prostate cancer (PC) lesions in patients with biochemical recurrence (BCR).
In trial... |
| 22.12.2023 | How Commercialisation Australia helped get us off the ground: Pharmaceutical research company tells | article-article-body
Sydney biotech startup Clarity Pharmaceuticals, which hopes to dramatically improve treatment outcomes for a range of serious diseases such as cancer, would not exist if not for the support of Commercialisation Australi... |
| 30.11.2023 | First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level | HIGHLIGHTS
Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity's 67Cu-SAR-bisPSMA at the 8GBq dose... |
| 30.11.2023 | Registrational Phase III CLARIFY trial in prostate cancer commences | SYDNEY, Nov. 30, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and... |
| 29.11.2023 | Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort | HIGHLIGHTS
Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has enrolled and treated 3 participants who received therapy with 67Cu-SAR-bisPSMA at the highe... |
| 07.11.2023 | Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial | SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and ... |
| 26.10.2023 | Clarity and PSI kick off SAR-bisPSMA Phase III | SYDNEY, Oct. 26, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and... |
| 03.10.2023 | First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial | SYDNEY, Oct. 3, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and ... |
| 25.08.2023 | First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial | Highlights
First participant of cohort 3 in the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been treated at the highest dose level of 12GBq.
Cohort 2 was recently... |
| 10.08.2023 | Clarity's theranostic prostate cancer trial advances to highest dose level | Highlights
Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been completed in 3 participants who received therapy with 67Cu SAR-bisPSMA at the dose lev... |
| 24.07.2023 | Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial | SYDNEY, July 24, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment ... |
| 04.07.2023 | Positive guidance from US FDA on Cu-64 SAR-bisPSMA Phase III trial in prostate cancer | Highlights
FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in prostate cancer
Phase III trial design based on 64Cu SAR-bisPSMA data package, including positive results from the completed PROPELLER trial
A total o... |
| 28.06.2023 | Clarity establishes a US Center of Excellence for Targeted Copper Theranostics | SYDNEY, June 28, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and... |
| 20.06.2023 | Clarity commences COMBAT theranostic prostate cancer trial in the US | SYDNEY, June 20, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and... |
| 24.05.2023 | Clarity's theranostic prostate cancer trial advances to cohort 2 | Highlights
Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy with 67Cu SAR-bisPSMA at the lowest dose level of 4GBq.
No dose limiting toxicities... |
| 09.02.2023 | US based COBRA diagnostic prostate cancer trial reaches recruitment target | SYDNEY, Feb. 9, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and ... |
| 21.11.2022 | IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer | SYDNEY, Nov. 21, 2022 /PRNewswire/ --
Highlights
Clarity's fifth successful Investigational New Drug (IND) application with the United States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin
A tota... |
| 04.11.2022 | NSW Health & Cicada Innovations celebrate Australia's biggest health startup training program with 1.1k participants in first year | SYDNEY, Nov. 4, 2022 /PRNewswire/ -- The NSW Health Commercialisation Training Program (CT Program), delivered by Australia's pioneer deep tech incubator Cicada Innovations and launched one year ago, hosted a Demo Day on 3rd November 2022 h... |
| 07.10.2022 | First patient treated in Clarity's therapeutic prostate cancer trial | Highlights
Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCTs) in patients with metas... |
| 05.09.2022 | Recruitment opens for Phase II trial in prostate cancer with Cu-64 SAR-Bombesin in the US | SYDNEY, Sept. 5, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and... |
| 23.08.2022 | Clarity advances to cohort 3 of the CL04 trial of SARTATE™ in paediatric neuroblastoma | Highlights
Cohort 2 completed in participants with neuroblastoma who received therapy with 67Cu SARTATE™ at a dose of 175MBq/kg body weight
No Dose Limiting Toxicities (DLTs) have been reported in cohort 1 and cohort 2
Safety Review Committ... |
| 20.07.2022 | Recruitment complete for Clarity's PROPELLER prostate cancer diagnostic trial | SYDNEY, July 20, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announc... |
| 06.06.2022 | IND approval from the US FDA for Phase II SAR-Bombesin imaging trial in prostate cancer | Highlights
IND approval received for SAR-Bombesin product, enabling a Phase II "SABRE" imaging trial to detect prostate cancer in up to 50 PSMA-negative participants in the US
Approximately 20% of prostate cancer patients with bio... |
| 26.05.2022 | Dr Neal Shore joins Clarity's Clinical Advisory Board | SYDNEY, May 26, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce... |
| 28.03.2022 | Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment | SYDNEY, March 28, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announ... |
| 24.03.2022 | New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer | SYDNEY, March 24, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announ... |
| 25.02.2022 | First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial | SYDNEY, Feb. 25, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announc... |
| 07.02.2022 | US FDA Study May Proceed letter for Clarity's Cu-64 SAR-bisPSMA trial in prostate cancer | SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce... |
| 01.02.2022 | Clarity advances to cohort 2 in the SARTATE™ neuroblastoma trial | SYDNEY, Feb. 1, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce... |
| 02.12.2021 | Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics | SYDNEY, Dec. 2, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Cardinal Health (N... |
| 01.12.2021 | Fifty percent recruitment milestone for PROPELLER prostate cancer trial | SYDNEY, Dec. 1, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce... |
| 10.11.2021 | Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed | Clarity Pharmaceuticals completes recruitment for the initial dosimetry phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCT) in patients with metastatic castrate-resist... |
| 30.09.2021 | Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US Clinical trials | SYDNEY, Sept. 30, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, and... |
| 25.08.2021 | First patient treated in Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial | SYDNEY, Aug. 25, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or the "Company"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the gro... |
| 28.07.2021 | Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial | SYDNEY, July 28, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has commenced its 64/67Cu SAR-bisPSMA theranostic clinic... |
| 11.05.2021 | Shaemus Gleason Appointed Executive Vice President US Operations at Clarity Pharmaceuticals | SYDNEY, May 11, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Shaemus Gleason as Executive Vice President U.... |
| 04.05.2021 | Clarity receives US FDA clearance of IND Application for its next-generation PSMA theranostic products | SYDNEY, May 4, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has received a response from the U.S. Food and Drug Admini... |
| 23.03.2016 | The 15 startup ideas set to share $8 million in government grants | Dr Alan Taylor, executive chairman of Clarity Pharmaceuticals
Fifteen innovative projects tackling issues from mental health and cancer to agriculture and recreation will share in more than $8 million in government grants as part of the fed... |
| 21.03.2016 | The 15 startup ideas set to share $8 million in government grants | Fifteen innovative projects tackling issues from mental health and cancer to agriculture and recreation will share in more than $8 million in government grants as part of the federal govenrment’s entrepreneurs’ program.
The Accelerating Com... |
| 02.05.2014 | How Commercialisation Australia helped get us off the ground: Pharmaceutical research company tells | Sydney biotech startup Clarity Pharmaceuticals, which hopes to dramatically improve treatment outcomes for a range of serious diseases such as cancer, would not exist if not for the support of Commercialisation Australia, according to its e... |
